Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
Parkinson's Disease
Interventions
DRUG

18-FDTBZ

"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."

Trial Locations (1)

333

Chang Gung Memory Hospital, Taoyuan District

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT02599753 - Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients | Biotech Hunter | Biotech Hunter